Filing search / Current reports / Phaserx, Inc. / Page 2

8-K

auasptpod zhnar4

27 Mar 17

PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

12:00am

8-K

0pgmeb 16m8h

8 Mar 17

Regulation FD Disclosure

12:00am

8-K

2d2olq8r 1s

6 Mar 17

Amendments to Articles of Incorporation or Bylaws

12:00am

8-K

9a6vtlp4

28 Nov 16

PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency

12:00am

8-K

seo0x4e

8 Nov 16

Regulation FD Disclosure

12:00am

8-K

gjy5mm8s5xtdfi

7 Nov 16

PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update

12:00am

8-K

67w6pcco2nt1g29u94zw

24 Aug 16

Departure of Directors or Certain Officers

12:00am

8-K

l2xdd3h1c 51

2 Aug 16

PhaseRx Reports Second Quarter 2016 Financial Results and Provides Corporate Update

12:00am

8-K

trorlk q6dp

21 Jun 16

PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases

12:00am

8-K

6fwuobbt3tredxabh

9 Jun 16

Entry into a Material Definitive Agreement

12:00am

8-K

t0b84 ywd47d

23 May 16

Unregistered Sales of Equity Securities

12:00am